Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series

Ku, Geoffrey Yuyat; Lopes, Gilberto; Chang, Alex

doi:10.1111/j.1743-7563.2010.01345.x

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination was well tolerated with limited grade 3/4 toxicity [61]. Good results were also reported by Ku GY et al [66] in a series of five cases (four with cirrhosis) treated with a combination of bevacizumab, oxaliplatin and doxorubicin (or liposomal doxorubicin); the AFP levels of four patients decreased by more than 50% compared with the baseline levels; one patient achieved radiographic complete response and one stable disease.…”

Section: Efficacy and Safety Of Chemotherapy With Oxaliplatin In Combinsupporting

confidence: 53%

Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China

Qin

Gong

2015

Hepat. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) characterized by insidious onset is a highly invasive malignance and has a rapid progress. The majority of patients, especially in Asian countries, present with locally advanced or distant metastatic disease at diagnosis and are not eligible for local treatment. Before the publication of the EACH study results showing the survival benefits of the FOLFOX 4 regimen in Chinese patients with advanced HCC, no chemotherapeutical drug or regimen was considered as systemic chemotherapy standard for this group of patients due to the lack of evidence-based recommendations. Oxaliplatin-containing regimens have shown clinical activity against advanced HCC with an acceptable safety profile. The aim of this article is to present a review of the scientific evidence mainly originating from China that supports the recommendation of oxaliplatin-based regimens for the treatment of Chinese patients with advanced HCC.

show abstract

Section: Efficacy and Safety Of Chemotherapy With Oxaliplatin In Combinsupporting

confidence: 53%

Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China

Qin

Gong

2015

Hepat. Oncol.

View full text Add to dashboard Cite

show abstract

Electrohydrodynamic atomization technologies for the preparation of fibrous NSAID buccal films

Nazari¹

2017

Pharmacoeconomics

View full text Add to dashboard Cite

Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series

Abstract: These data add to the growing phase II data that bevacizumab-containing regimens are active in advanced HCC patients. Further evaluation of regimens containing bevacizumab with oxaliplatin and/or doxorubicin may be warranted.

Cited by 2 publications

References 17 publications

Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China

Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China

Electrohydrodynamic atomization technologies for the preparation of fibrous NSAID buccal films

Contact Info

Product

Resources

About